Browsing by Author "Sahin G."

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Diagnostic yield of upper gastrointestinal endoscopy in the evaluation of iron deficiency anemia in older children and adolescents
    (2011) Gulen H.; Kasirga E.; Yildirim S.A.; Kader S.; Sahin G.; Ayhan S.
    Iron deficiency anemia (IDA) is frequent in childhood. Inadequate nutrition and gastrointestinal malabsorption are the frequent causes of IDA in children. But reduced iron absorption and insidious blood loss from the gastrointestinal tract has been identified as the most frequent causes of IDA in older children and adolescents. Therefore the authors evaluated the frequency and etiologies of the upper gastrointestinal system pathologies causing IDA in older pediatric population. Patients with known hematological or chronic diseases, heavy menstrual flow, and obvious blood loss were excluded from the study. Forty-four children between the ages of 9.5 and 17.5 years and diagnosed with IDA were enrolled. They underwent upper gastrointestinal endoscopy and biopsy from esophagus, stomach, and duodenum. Mean age and hemoglobin (Hb) levels of study group (32 boys, and 12 girls) were 14.6 ± 2.0 years and 7.9 ± 1.8 g/dL, respectively. Only 1 patient had a positive serology testing with anti-tissue transglutaminase and small bowel biopsy correlating with celiac disease. Endoscopy revealed abnormal findings in 25 (56.8%) patients (21 endoscopic antral gastritis, 2 active duodenal ulcers, and 2 duodenal polyps). Helicobacter pylori (HP) infection was identified by using antral histopathological evaluation in 19 of 44 children (43.2%). In 2 of duodenal samples, one patient had celiac disease, and the other one was diagnosed as giardiasis. In conclusion, there are different etiologies resulting in IDA in older children and adolescents. When older children and adolescents are found to have iron deficiency, HP infection and other gastrointestinal pathologies should be ruled out before iron deficiency treatment. © 2011 Informa Healthcare USA, Inc.
  • No Thumbnail Available
    Item
    Removal of Cr ions from aquatic solutions using olive leaves as low-cost bio-sorbent
    (Atomic Spectroscopy Press Limited, 2020) Sahin G.; Aslan A.; Tuzen M.; Sarı A.
    Contamination of water by chromium (Cr) creates serious pollution in terms of the environment and public health, since its different forms become released into air, water, soil and residential areas. In the present work, olive leaf powder (OLP) was evaluated as a novel low-cost sorbent due to its various functional groups such as amide, hydroxyl, carboxyl, and carbonyl which are responsible for the bio-removal of chromium ions from aqueous solutions. The chemical functional groups and microstructure of the OLP bio-sorbent were characterized by the Fourier Transform Infrared (FT-IR) spectroscopy and scanning electron microscopy (SEM) techniques. The bio-sorption conditions were optimized as pH 4, contact time 60 min, bio-sorbent dosage 40 g/L, temperature 40 °C. The bio-sorption isotherm was well fitted to the Langmuir model, and the predicted maximum bio-removal capacity of the OLP was estimated at 42.4 mg/g under the above-mentioned experimental conditions. The reuse performance of the bio-sorbent was determined after repeated sorption/desorption cycles. The thermodynamic examination showed that the chromium sorption by OLP was endothermic in thermal nature. The kinetic evaluations indicated that the bio-sorption process well followed with the pseudo-second-order model. The overall results demonstrated that the OLP can be thought as a potential bio-sorbent for cleaning of chromium-contaminated water and wastewater due to its advantageous properties such as low cost, availability, renewable nature, and remarkable bio-sorption capacity. © 2020, Atomic Spectroscopy Press Limited. All rights reserved.
  • No Thumbnail Available
    Item
    Guideline on pregnancy and diabetes by the society of specialists in perinatology (PUDER), Turkey
    (Ortadog u Reklam Tanitim Yayincilik Turizm Egitim Insaat Sanayi ve Ticaret A.S., 2020) Bayram M.; Asyali Biri A.; Esim Büyükbayrak E.; Daglar H.K.; Ercan F.; Gürsoy Erzincan S.; Çorbacioglu Esmer A.; Inan C.; Kanit H.; Kara Ö.; Katlan D.C.; Nas T.; Öcal E.; Sagsöz N.; Sanhal C.Y.; Sahin G.; Timur H.; Turhan U.; Gençosmanoglu Türkmen G.; Türkyilmaz G.; Bilgin Yanik F.F.; Yüksel M.A.
    Diabetes mellitus (DM) is the most common endocrinologic problem in pregnancy. In Turkey, the reported prevalance is between 1.9-27.9%, with an average of 7.7%. While some of these cases are pregestational diabetes (PGDM), about 90% are detected during the pregnancy for the first time and diagnosed as gestational diabetes (GDM). Diabetes in pregnancy confers serious risks regarding the fetus, newborn and the mother. Therefore, we offer GDM screening for all pregnant women preferantially between 24-28 weeks of gestation. Either one-step 75-g oral glucose tolerance test (OGTT) or two-step 50-g glucose challenge test and 100-g OGTT may be used for the screening and diagnosis. In pregnancies with high-risk for DM, screening should be performed earlier, if possible, in the first antenatal visit. When GDM is diagnosed, maternal glycemic control is tried to be achieved by diet and exercise program, and if necessary, by using insulin. The use of metformin or glyburide in pregnancy is also possible. In women with the diagnosis of DM before pregnancy, preconceptional control of plasma glucose levels is of utmost importance in order to prevent adverse pregnancy outcomes. In pregnancies with GDM regulated by diet and exercise, pregnancy follow-up may be performed as in the low risk group without any pregnancy complications. If maternal or fetal distress is not observed, delivery is planned between 39+0 -40+6 weeks. Although caesarean section is recommended when estimated fetal weight is 4500 g or more, the mode of delivery may be decided more appropriately on a case-by-case basis. Copyright © 2020 by Türkiye Klinikleri.
  • No Thumbnail Available
    Item
    Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study
    (Multidisciplinary Digital Publishing Institute (MDPI), 2025) Tünbekici S.; Yuksel H.C.; Acar C.; Sahin G.; Orman S.; Majidova N.; Coskun A.; Seyyar M.; Dilek M.S.; Kara M.; Dıslı A.K.; Demir T.; Kolkıran N.; Sahbazlar M.; Demırcıler E.; Kuş F.; Aytac A.; Menekse S.; Yucel H.; Biter S.; Koseci T.; Unsal A.; Ozveren A.; Sevınc A.; Goker E.; Gürsoy P.
    Background/Objectives: In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate the effectiveness and safety of regorafenib as a third-line treatment for patients with recurrent glioblastoma who progressed while taking bevacizumab-based therapy. Methods: This retrospective, multicenter study in Turkey included 65 patients treated between 2021 and 2023 across 19 oncology centers. The main inclusion criteria were histologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma, progression after second-line bevacizumab-based treatment, and an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2. Patients received regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle. Results: The median age of the patients was 53 years (18–67 years), with a median progression-free survival of 2.5 months (95% Confidence Interval: 2.23–2.75) and a median overall survival of 4.1 months (95% CI: 3.52–4.68). The median overall survival was improved in patients who received subsequent therapy after regorafenib treatment compared with those who did not (p = 0.022). Progression-free survival was longer in patients with ECOG 0–1 than in those with ECOG 2 (p = 0.042). The safety profile was consistent with that of the REGOMA trial, with no drug-related deaths observed. Conclusions: Regorafenib shows good efficacy and safety as a third-line treatment for recurrent glioblastoma after bevacizumab-based therapy. This study supports the use of regorafenib and emphasizes the need for further randomized studies to validate its role and optimize treatment strategies. © 2024 by the authors.